

ML-193


04/20

ALTERNATE NAMES:

N-[4-[(3,4-dimethyl-1,2-oxazol-5-yl)sulfamoyl]phenyl]-6,8-dimethyl-2-pyridin-2-ylquinoline-4-carboxamide;
 N-[4-[[[(3,4-Dimethyl-5-isoxazolyl)amino]sulfonyl]phenyl]-6,8-dimethyl-2-(2-pyridinyl)-4-quinolinecarboxamide; N-[4-[(3,4-dimethylisoxazol-5-yl)sulfamoyl]phenyl]-6,8-dimethyl-2-(2-pyridyl)cinchoninamide; CID-1261822

CATALOG #:

B3016-5 5 mg
 B3016-25 25 mg

STRUCTURE:

MOLECULAR FORMULA:
 $C_{28}H_{25}N_5O_4S$
MOLECULAR WEIGHT:

527.6

CAS NUMBER:

713121-80-3

APPEARANCE:

White solid

PURITY:

98%

SOLUBILITY:

3 mg/ml in DMF
 2 mg/ml in DMSO
 0.1 mg/ml in Ethanol

DESCRIPTION:

ML-193 is a selective quinoline aryl sulfonamide antagonist for GPR55, a lysophosphatidylinositol (LPI)-sensitive receptor that is also involved in cannabinoid signaling. It inhibits GPR55 with an IC_{50} of 221 nM. It also inhibits GPR55-dependent ERK phosphorylation with an IC_{50} of 65 nM and blocks translocation of PKC β II. Pretreatment with ML-193 (1 μ g/0.5 μ l, 15 min before LPI), antagonized the LPI-induced nociception in a rat model.

STORAGE TEMPERATURE:

-20°C. Store in the dark. Product is light sensitive. Protect from air. Store under desiccating conditions.

HANDLING:

Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCES:

1. Deliu, E., Sperow, M., Console-Bram, L., et al. The lysophosphatidylinositol receptor GPR55 modulates pain perception in the periaqueductal gray. *Mol.Pharmacol.* 88(2), 265-272 (2015).
2. Heynen-Genel, S., Dahl, R., Shi, S., et al. Screening for selective ligands for GPR55 - antagonists. *NIH Mol.Libraries* (2010).

RELATED PRODUCTS:

Arachidonoyl 2'-Chloroethylamide (Cat. No. B3015)
 2-Arachidonoylglycerol (Cat. No. B2992)
 BAY 59-3074 (Cat. No. B1247)
 Leelamine hydrochloride (Cat. No. 2717)
 WIN 55,212-2 Mesylate (Cat. No. B3012)

DISCLAIMER:

FOR RESEARCH USE ONLY! Not to be used on humans.